Melatonin and Cancer: The Science, the Mechanisms, and the Doris Loh Revolution

Introduction: The Most Underestimated Molecule in Oncology

Ask most people what melatonin does, and they will tell you it helps you sleep. Ask most oncologists, and they will likely say the same. But ask Doris Loh — an independent researcher whose meticulous, deeply referenced work on melatonin has quietly revolutionized how a growing community of integrative medicine practitioners and researchers understand this molecule — and you will get a very different answer.

Melatonin is not primarily a sleep hormone. It is one of the most ancient, ubiquitous, and multifunctional molecules in biology — present in virtually every living organism from single-celled algae to humans. It is a master antioxidant, a mitochondrial protector, an immune modulator, an epigenetic regulator, a metabolic switch, and — as the evidence increasingly shows — one of the most potent and versatile anti-cancer agents in the human body.

The tragedy is that most people — including most cancer patients — are profoundly deficient in melatonin, due to artificial light exposure at night, aging, stress, and the very cancer treatments designed to save their lives. And most of those who do supplement with melatonin take doses so small — 0.5 to 5 mg — that they barely scratch the surface of its therapeutic potential.

In this post, we explore the full depth of melatonin's anti-cancer science, with particular attention to the groundbreaking work of Doris Loh, whose research has illuminated melatonin's role in electron transport, mitochondrial function, and cancer metabolism in ways that are transforming how integrative oncologists think about this remarkable molecule.

Who Is Doris Loh? A Researcher Who Changed the Conversation

Doris Loh is an independent researcher based in the United States who has dedicated years to synthesizing the scientific literature on melatonin into a comprehensive, mechanistically coherent framework. She is not affiliated with a university or pharmaceutical company — she is a citizen scientist in the truest sense, driven by intellectual rigor and a commitment to making complex science accessible.

Her work, published through her website, research papers, and collaborations with academic researchers, has focused particularly on:

• Melatonin's role as an electron donor and its interactions with the mitochondrial electron transport chain
• The distinction between melatonin's receptor-mediated effects and its receptor-independent, direct biochemical effects
• Melatonin's role in regulating the NAD+/NADH ratio and its implications for cancer metabolism
• The quantum biology of melatonin — how its unique molecular structure allows it to function as a biological semiconductor
• The critical importance of dose in melatonin's anti-cancer activity, and why pharmacological doses (far above typical supplement doses) are necessary for therapeutic effects
• Melatonin's interactions with ascorbate (vitamin C) and other antioxidants in a coordinated electron transfer network

Loh's work has been cited by and collaborated with academic researchers including Dr. Russel Reiter — the world's foremost melatonin researcher and author of over 1,600 published papers on melatonin — and has influenced the thinking of integrative oncologists including Dr. Paul Marik, whose CARE protocol features high-dose melatonin as a central component.

Her most important contribution, perhaps, is reframing melatonin not as a hormone that happens to have some antioxidant properties, but as a fundamental electron management molecule whose role in mitochondrial function and cancer metabolism is central rather than peripheral.

Melatonin's Biochemistry: Beyond the Sleep Hormone Narrative

Synthesis and Distribution

Melatonin (N-acetyl-5-methoxytryptamine) is synthesized from tryptophan through a four-step enzymatic pathway: tryptophan → 5-hydroxytryptophan → serotonin → N-acetylserotonin → melatonin. The pineal gland is the primary source of circulating melatonin, with production peaking at night in response to darkness and suppressed by light — particularly blue light.

But the pineal gland is not the only source of melatonin. Doris Loh has emphasized a point that is often overlooked in mainstream discussions: melatonin is also produced locally in virtually every tissue in the body, including the gut (which produces far more melatonin than the pineal gland), the immune cells, the skin, the retina, and — critically — within mitochondria themselves.

This local, mitochondrial production of melatonin is not regulated by the light-dark cycle and does not appear in blood measurements. It is a separate, autonomous system that serves a fundamentally different purpose from circulating pineal melatonin — and it is this mitochondrial melatonin that Loh argues is most critical for cancer prevention and treatment.

Melatonin as an Electron Donor: Loh's Central Insight

The most important and original contribution of Doris Loh's work is her detailed analysis of melatonin as an electron donor in the mitochondrial electron transport chain (ETC).

The mitochondrial ETC is the series of protein complexes (Complexes I–IV) through which electrons are transferred from NADH and FADH₂ to oxygen, generating the proton gradient that drives ATP synthesis. This process is the foundation of oxidative phosphorylation — the efficient energy production that normal cells use and that cancer cells have largely abandoned in favor of glycolysis.

Loh's research, synthesizing data from multiple published studies, demonstrates that melatonin functions as an electron donor at Complex I of the mitochondrial ETC. Specifically:

• Melatonin donates electrons to Complex I, supporting the reduction of NAD+ to NADH and enhancing electron flow through the ETC.
• This electron donation supports the NAD+/NADH ratio, which is a critical regulator of cellular metabolism. A high NAD+/NADH ratio favors oxidative metabolism; a low ratio (as seen in cancer cells) favors glycolysis.
• By supporting Complex I function, melatonin helps maintain the mitochondrial membrane potential (ΔΨm) that drives ATP synthesis.
• Melatonin's metabolites — particularly AFMK (N1-acetyl-5-methoxykynuramine) and AMK (N1-acetyl-5-methoxykynuramine) — are also potent antioxidants and electron donors, creating a cascade of antioxidant protection that Loh describes as a "melatonin antioxidant cascade."

This framework has profound implications for cancer. Cancer cells have dysfunctional mitochondria with impaired Complex I activity — one of the primary reasons they cannot efficiently perform oxidative phosphorylation and must rely on glycolysis. By supporting Complex I function in normal cells, melatonin helps maintain the metabolic health that protects against cancer. And by generating oxidative stress in cancer cells whose antioxidant defenses are already compromised, high-dose melatonin may selectively damage cancer cell mitochondria while protecting normal cell mitochondria.

The NAD+ Connection: Melatonin, SIRT1, and Metabolic Regulation

Loh's work has also illuminated melatonin's relationship with NAD+ — a coenzyme that has become one of the hottest topics in longevity and cancer research.

NAD+ is essential for:

• Oxidative phosphorylation (as an electron carrier)
• DNA repair (as a substrate for PARP enzymes)
• Epigenetic regulation (as a substrate for sirtuin deacetylases)
• Immune function
• Circadian rhythm regulation

Cancer cells have severely depleted NAD+ levels due to their high PARP activity (repairing the DNA damage caused by their genomic instability) and their metabolic reprogramming. This NAD+ depletion further impairs their ability to perform oxidative phosphorylation, reinforcing their glycolytic dependence.

Melatonin influences NAD+ metabolism through several mechanisms:

• SIRT1 activation: Melatonin activates SIRT1, a NAD+-dependent deacetylase that regulates metabolism, DNA repair, and circadian rhythms. SIRT1 activation by melatonin promotes oxidative metabolism and suppresses glycolysis — pushing cells away from the Warburg Effect.
• NAMPT regulation: Melatonin influences NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the NAD+ salvage pathway, affecting overall NAD+ availability.
• PGC-1α activation: Through SIRT1, melatonin activates PGC-1α, the master regulator of mitochondrial biogenesis, promoting the growth of new, healthy mitochondria in normal cells.

This NAD+/SIRT1/PGC-1α axis connects melatonin to the deepest levels of metabolic regulation — and to the metabolic theory of cancer championed by Dr. Thomas Seyfried. By supporting NAD+ metabolism and mitochondrial biogenesis in normal cells, melatonin helps maintain the metabolic health that is the foundation of cancer resistance.

Melatonin's Anti-Cancer Mechanisms: A Comprehensive Overview

1. Direct Antioxidant and Pro-Oxidant Activity

Melatonin is one of the most potent antioxidants known — more effective than vitamins C and E on a molar basis, and unique in its ability to cross all biological membranes including the blood-brain barrier and the inner mitochondrial membrane. Its antioxidant activity operates through multiple mechanisms:

• Direct free radical scavenging: Melatonin directly neutralizes hydroxyl radicals, superoxide anions, hydrogen peroxide, singlet oxygen, and peroxynitrite — the most damaging reactive oxygen and nitrogen species.
• Antioxidant enzyme upregulation: Melatonin upregulates superoxide dismutase (SOD), catalase, and glutathione peroxidase — the body's primary antioxidant enzymes.
• Glutathione support: Melatonin stimulates glutathione synthesis and recycling, supporting the most important intracellular antioxidant system.
• The melatonin antioxidant cascade: As Loh has detailed, melatonin's metabolites (AFMK, AMK) are themselves potent antioxidants, creating a cascade where one melatonin molecule can neutralize multiple free radicals through successive metabolic transformations.

Paradoxically, at the pharmacological doses used in cancer treatment, melatonin can also act as a pro-oxidant in cancer cells — generating reactive oxygen species that overwhelm cancer cells' already-compromised antioxidant defenses. This selective pro-oxidant activity in cancer cells, combined with antioxidant protection of normal cells, is one of melatonin's most therapeutically valuable properties.

Doris Loh has been particularly emphatic about this dose-dependent duality: at low doses (0.5–5 mg), melatonin acts primarily as an antioxidant. At pharmacological doses (20–200 mg or higher), it can generate selective oxidative stress in cancer cells while protecting normal cells through its antioxidant cascade. This is why dose matters enormously in melatonin's anti-cancer applications.

2. Mitochondrial Protection and Cancer Metabolic Disruption

Building on Loh's electron transport framework, melatonin's effects on mitochondria are central to its anti-cancer activity:

• Normal cell mitochondrial protection: In normal cells, melatonin supports Complex I function, maintains mitochondrial membrane potential, reduces mitochondrial ROS production, and promotes mitochondrial biogenesis through PGC-1α. This creates metabolically healthy, cancer-resistant cells.
• Cancer cell mitochondrial disruption: In cancer cells with dysfunctional mitochondria, high-dose melatonin generates mitochondrial ROS that exceeds the cancer cell's antioxidant capacity, disrupts the mitochondrial membrane potential, and triggers cytochrome c release and apoptosis through the intrinsic pathway.
• Warburg Effect reversal: By supporting oxidative phosphorylation and suppressing glycolysis (through SIRT1/PGC-1α activation and HIF-1α suppression), melatonin pushes cells away from the Warburg Effect — creating conditions hostile to cancer cell survival.
• Mitophagy regulation: Melatonin regulates mitophagy (selective autophagy of damaged mitochondria), helping normal cells maintain a healthy mitochondrial pool while potentially disrupting cancer cells' mitochondrial quality control.

3. Immune System Enhancement

Melatonin is a powerful immunomodulator with broad effects on both innate and adaptive immunity:

• Natural killer (NK) cell enhancement: Melatonin significantly increases NK cell number and cytotoxic activity — NK cells are the immune system's primary cancer surveillance cells, capable of recognizing and destroying cancer cells without prior sensitization.
• T cell activation: Melatonin promotes the differentiation and activation of cytotoxic CD8+ T cells, which are essential for adaptive anti-tumor immune responses.
• Macrophage M1 polarization: Melatonin promotes anti-tumor M1 macrophage polarization, shifting the tumor microenvironment from immunosuppressive to immunostimulatory.
• Th1/Th2 balance: Melatonin promotes Th1 immune responses (which favor anti-tumor immunity) over Th2 responses (which are associated with immune tolerance of tumors).
• Cytokine modulation: Melatonin increases pro-inflammatory, anti-tumor cytokines (IL-2, IL-12, IFN-γ) while reducing immunosuppressive cytokines (IL-10, TGF-β) in the tumor microenvironment.
• Thymus support: Melatonin supports thymic function and prevents thymic involution — the age-related shrinkage of the thymus that reduces T cell production and immune competence.

This comprehensive immune enhancement is particularly relevant for cancer patients who have undergone immunosuppressive chemotherapy, which dramatically depletes NK cells, T cells, and other immune effectors. Melatonin may help restore immune surveillance during and after chemotherapy.

4. Anti-Proliferative and Pro-Apoptotic Effects

Melatonin directly inhibits cancer cell proliferation and promotes apoptosis through multiple molecular mechanisms:

• Cell cycle arrest: Melatonin induces G1 phase cell cycle arrest in cancer cells through upregulation of p21 and p27 (cyclin-dependent kinase inhibitors) and downregulation of cyclin D1 and CDK4/6.
• Apoptosis induction: Melatonin activates both the intrinsic (mitochondrial) and extrinsic (death receptor) apoptotic pathways in cancer cells, through upregulation of BAX, PUMA, and caspase activation.
• Survivin suppression: Melatonin reduces expression of survivin — an anti-apoptotic protein that is overexpressed in most cancers and is a major driver of treatment resistance.
• Telomerase inhibition: Melatonin has been shown to inhibit telomerase activity in cancer cells. Telomerase is the enzyme that allows cancer cells to maintain their telomeres and achieve replicative immortality — one of the hallmarks of cancer.
• p53 activation: Melatonin activates and stabilizes p53, the master tumor suppressor, amplifying its pro-apoptotic and cell cycle arrest functions.

5. Anti-Angiogenic Effects

Tumors require new blood vessel formation (angiogenesis) to grow beyond a few millimeters. Melatonin suppresses tumor angiogenesis through:

• VEGF suppression: Melatonin reduces VEGF (vascular endothelial growth factor) expression in cancer cells, cutting off the primary signal for tumor blood vessel recruitment.
• HIF-1α inhibition: Melatonin suppresses HIF-1α, the master transcription factor that drives VEGF expression and angiogenesis in hypoxic tumor regions.
• MMP inhibition: Melatonin reduces matrix metalloproteinase (MMP) activity, impairing the tissue remodeling that angiogenesis requires.
• Endothelial cell effects: Melatonin directly inhibits the proliferation and migration of endothelial cells (the cells that form blood vessel walls) in response to tumor-derived angiogenic signals.

6. Anti-Metastatic Effects

Melatonin inhibits cancer metastasis — the spread of cancer to distant organs — through multiple mechanisms:

• EMT inhibition: Melatonin suppresses epithelial-to-mesenchymal transition (EMT) — the process by which cancer cells acquire the invasive, migratory properties needed for metastasis — by upregulating E-cadherin and downregulating N-cadherin, vimentin, and SNAI1.
• MMP suppression: Melatonin reduces MMP-2 and MMP-9 expression, impairing cancer cells' ability to degrade the extracellular matrix and invade surrounding tissue.
• Integrin modulation: Melatonin modulates integrin expression, reducing cancer cell adhesion to blood vessel walls — a critical step in metastatic colonization.
• Platelet aggregation inhibition: Cancer cells exploit platelet aggregation to protect themselves in the bloodstream and facilitate metastatic seeding. Melatonin's anti-platelet effects may reduce this protection.

7. Epigenetic Regulation

Melatonin has significant epigenetic effects that are relevant to cancer prevention and treatment:

• DNA methylation regulation: Melatonin influences DNA methyltransferase (DNMT) activity, potentially reactivating silenced tumor suppressor genes through epigenetic demethylation.
• Histone modification: Through SIRT1 activation, melatonin influences histone deacetylation patterns, altering gene expression in ways that suppress oncogene activity and restore tumor suppressor function.
• microRNA regulation: Melatonin modulates the expression of multiple microRNAs with tumor suppressor or oncogenic functions, adding another layer of epigenetic anti-cancer activity.
• Circadian clock restoration: Melatonin is the master regulator of circadian rhythms, and circadian disruption is increasingly recognized as a cancer risk factor. By restoring circadian clock gene expression (CLOCK, BMAL1, PER, CRY), melatonin may restore the circadian regulation of cell cycle, DNA repair, and immune function that is disrupted in cancer.

8. Hormone Modulation: Aromatase Inhibition and Estrogen Regulation

For hormone-sensitive cancers — particularly breast and prostate cancer — melatonin's hormonal effects are particularly important:

• Aromatase inhibition: Melatonin inhibits aromatase, the enzyme that converts androgens to estrogens. This reduces estrogen production in peripheral tissues (fat, breast tissue), which is particularly relevant for postmenopausal breast cancer where peripheral aromatization is the primary source of estrogen.
• Estrogen receptor modulation: Melatonin modulates estrogen receptor (ER) expression and sensitivity, reducing the proliferative response of ER+ breast cancer cells to estrogen.
• Androgen receptor effects: In prostate cancer, melatonin has been shown to modulate androgen receptor signaling, potentially reducing androgen-driven tumor growth.
• Insulin and IGF-1 reduction: Melatonin reduces insulin and IGF-1 levels, both of which are important growth factors for many cancers.

The Dose Question: Why Most People Are Taking Too Little

One of Doris Loh's most important and controversial contributions is her detailed analysis of melatonin dosing for anti-cancer applications. Her conclusion, supported by a careful reading of the pharmacological literature, is unambiguous: the doses most people take for sleep (0.5–5 mg) are pharmacologically insufficient for meaningful anti-cancer activity.

Here is the reasoning:

• Physiological vs. pharmacological dosing: The pineal gland produces approximately 0.1–0.3 mg of melatonin per night. Doses of 0.5–5 mg are in the physiological range — they restore or slightly exceed normal nighttime melatonin levels. Pharmacological doses (20–200 mg or higher) achieve plasma concentrations orders of magnitude above physiological levels and engage different molecular mechanisms.
• The clinical trial evidence: The most compelling clinical evidence for melatonin's anti-cancer activity comes from studies using doses of 20–200 mg per day. A landmark meta-analysis by Mills et al. published in the Journal of Pineal Research (2005) analyzed 10 randomized controlled trials of melatonin in cancer patients and found that melatonin supplementation significantly improved one-year survival rates — with a relative risk of death of 0.66 (a 34% reduction in mortality) across all cancer types studied. The doses used in these trials ranged from 10 to 40 mg per day.
• Loh's electron transport framework: For melatonin to function as an electron donor at Complex I of the mitochondrial ETC and generate the selective pro-oxidant effects in cancer cells that Loh describes, pharmacological concentrations are required. At physiological doses, melatonin's antioxidant effects predominate; at pharmacological doses, the pro-oxidant, anti-cancer effects emerge.
• Safety at high doses: Melatonin has an extraordinary safety profile even at very high doses. Studies using doses of 300–1,000 mg per day in humans have found no serious adverse effects. The most common side effect at higher doses is daytime drowsiness, which can be managed by taking melatonin at bedtime.

Dr. Paul Marik's CARE protocol recommends 20–80 mg of melatonin at bedtime for cancer patients — a dose range that reflects the clinical trial evidence and Loh's pharmacological analysis. Some practitioners use even higher doses in specific contexts.

Melatonin and Chemotherapy: Enhancing Efficacy, Reducing Toxicity

One of the most clinically significant findings in melatonin cancer research is its ability to simultaneously enhance chemotherapy effectiveness and reduce chemotherapy toxicity — a combination that is extremely rare and highly valuable.

Multiple randomized controlled trials have demonstrated this dual benefit:

• A 2002 study by Lissoni et al. in the British Journal of Cancer found that melatonin (20 mg/day) combined with chemotherapy significantly improved response rates and one-year survival compared to chemotherapy alone in patients with metastatic non-small cell lung cancer.
• A 2003 study by the same group found similar benefits in metastatic colorectal cancer patients.
• Multiple studies have shown that melatonin reduces chemotherapy-induced myelosuppression (bone marrow suppression), thrombocytopenia (low platelet count), neurotoxicity, and cardiotoxicity.
• Melatonin has been shown to reduce the severity of chemotherapy-induced nausea, fatigue, and weight loss.
• A 2010 meta-analysis of 8 randomized trials found that melatonin significantly improved complete response, partial response, and one-year survival rates when combined with chemotherapy or radiation, while reducing treatment-related toxicity.

The mechanisms underlying these dual benefits are consistent with Loh's framework: melatonin's antioxidant cascade protects normal cells (including bone marrow cells, neurons, and cardiomyocytes) from chemotherapy-induced oxidative damage, while its pro-oxidant effects in cancer cells enhance the cytotoxic activity of chemotherapy.

Melatonin and Radiation Therapy

Similar dual benefits have been observed when melatonin is combined with radiation therapy:

• Melatonin acts as a radioprotector for normal tissue, reducing radiation-induced DNA damage in healthy cells through its antioxidant cascade.
• Simultaneously, melatonin may act as a radiosensitizer for cancer cells, enhancing radiation-induced apoptosis through its pro-oxidant effects and p53 activation.
• Melatonin has been shown to reduce radiation-induced fatigue, mucositis, and cognitive impairment.
• Animal studies have shown that melatonin combined with radiation produces greater tumor control than radiation alone, while reducing normal tissue damage.

Cancer Stem Cells: Melatonin's Overlooked Target

Cancer stem cells (CSCs) — the treatment-resistant subpopulation responsible for tumor recurrence — are an important target of melatonin's anti-cancer activity:

• Melatonin has been shown to reduce CSC markers (CD44+/CD24-, ALDH1+) in breast, colorectal, and other cancers.
• It suppresses CSC self-renewal through inhibition of WNT/β-catenin and Notch signaling — two pathways essential for CSC maintenance.
• Melatonin reduces tumor sphere formation (a laboratory measure of CSC activity) in multiple cancer types.
• By targeting CSCs, melatonin may help prevent the recurrence that occurs when treatment-resistant CSCs survive conventional therapy and regenerate the tumor.

Doris Loh has emphasized that melatonin's ability to target CSCs is closely linked to its mitochondrial effects: CSCs are characterized by low mitochondrial activity and high glycolytic dependence, making them particularly vulnerable to melatonin's metabolic disruption at pharmacological doses.

The Circadian Connection: Light, Darkness, and Cancer Risk

Melatonin's role in cancer cannot be fully understood without appreciating its relationship to circadian rhythms and light exposure. The evidence linking circadian disruption to cancer risk is compelling:

• Night shift workers — who experience chronic circadian disruption and suppressed melatonin production — have significantly elevated rates of breast, colorectal, and prostate cancer. The International Agency for Research on Cancer (IARC) has classified shift work involving circadian disruption as a probable human carcinogen (Group 2A).
• Blind women, who cannot perceive light and therefore have consistently high melatonin levels, have significantly lower rates of breast cancer than sighted women.
• Exposure to artificial light at night (ALAN) — even at low intensities — suppresses melatonin production and is associated with increased cancer risk in epidemiological studies.
• Blue light (from screens, LED lighting) is particularly potent at suppressing melatonin, as it falls within the peak sensitivity range of the melanopsin photoreceptors that regulate pineal melatonin production.

Loh has written extensively about the importance of light hygiene — minimizing blue light exposure in the evening, sleeping in complete darkness, and using blue-light-blocking glasses — as foundational strategies for maintaining endogenous melatonin production. These behavioral interventions, combined with melatonin supplementation, create the most favorable melatonin environment for cancer prevention and treatment.

Practical Protocol: How to Use Melatonin for Cancer Support

Based on the clinical evidence, Doris Loh's research, and Dr. Marik's CARE protocol, the following practical guidance applies to melatonin use in cancer support:

Dosing

• For cancer prevention and general health: 5–20 mg at bedtime
• For active cancer treatment support (per Marik's CARE protocol): 20–80 mg at bedtime
• For specific high-dose protocols: Some practitioners use 100–200 mg or higher under medical supervision
• Start low and increase gradually: Begin with 5–10 mg and increase over several weeks to allow the body to adapt

Timing

• Always take melatonin at bedtime — it is most effective when taken in alignment with the natural melatonin surge (approximately 9–10 PM for most people)
• Taking melatonin during the day disrupts circadian rhythms and reduces its effectiveness

Form

• Immediate-release melatonin achieves peak plasma levels within 30–60 minutes and is appropriate for most applications
• Extended-release melatonin maintains elevated levels throughout the night and may be preferable for some applications
• Sublingual melatonin achieves faster absorption and higher peak levels than oral tablets

Light Hygiene

• Avoid blue light exposure (screens, LED lighting) for 2–3 hours before bedtime
• Use blue-light-blocking glasses in the evening
• Sleep in complete darkness — even small amounts of light can suppress melatonin production
• Consider red or amber lighting in the evening, which does not suppress melatonin

Synergistic Combinations

Doris Loh has written about melatonin's synergistic interactions with other molecules, particularly:

• Vitamin C (ascorbate): Loh has described a coordinated electron transfer network between melatonin and ascorbate, where they work together to recycle each other and maintain antioxidant capacity. This synergy is one reason why combining high-dose melatonin with IV or liposomal vitamin C may be particularly powerful.
• Vitamin D3: Melatonin and vitamin D3 have complementary immune-modulating and anti-cancer effects, with some evidence of synergistic interaction.
• Magnesium: Magnesium is required for melatonin synthesis and supports its mitochondrial effects.
• NAD+ precursors (NMN, NR): Given melatonin's role in NAD+ metabolism, combining it with NAD+ precursors may amplify its mitochondrial and anti-cancer effects.

Cancer Types with the Strongest Evidence for Melatonin

Melatonin has been studied across virtually all cancer types. The strongest evidence exists for:

• Breast cancer: Particularly ER+ breast cancer, where melatonin's aromatase inhibition and estrogen receptor modulation provide targeted hormonal benefits in addition to its general anti-cancer mechanisms.
• Lung cancer: Multiple clinical trials by Lissoni et al. demonstrating improved survival with melatonin combined with chemotherapy.
• Colorectal cancer: Strong preclinical and clinical evidence for anti-proliferative and pro-apoptotic effects.
• Prostate cancer: Androgen receptor modulation and general anti-cancer mechanisms.
• Glioblastoma: Melatonin crosses the blood-brain barrier and has shown anti-tumor activity in GBM models; its ability to protect normal brain tissue from radiation damage is particularly valuable.
• Ovarian cancer: Anti-proliferative, pro-apoptotic, and anti-angiogenic effects.
• Hepatocellular carcinoma: Anti-proliferative effects and liver-protective properties.

Conclusion: Reclaiming Melatonin's True Identity

Melatonin is not a sleep supplement. It is one of the most ancient, versatile, and powerful molecules in biology — a master antioxidant, mitochondrial protector, immune enhancer, epigenetic regulator, and anti-cancer agent whose full therapeutic potential has been obscured by its popular identity as a sleep aid.

The work of Doris Loh has been instrumental in revealing the deeper molecular biology of melatonin — particularly its role as an electron donor in the mitochondrial electron transport chain, its regulation of the NAD+/NADH ratio, and its dose-dependent shift from antioxidant to selective pro-oxidant in cancer cells. Her research, synthesized with the clinical trial work of Dr. Paolo Lissoni, the basic science of Dr. Russel Reiter, and the clinical protocols of Dr. Paul Marik, provides a comprehensive and compelling framework for understanding melatonin as a central pillar of integrative cancer care.

For cancer patients, the implications are clear: melatonin at pharmacological doses — not the 1–3 mg doses sold for sleep — is a scientifically grounded, remarkably safe, and potentially powerful component of a comprehensive cancer care strategy. Combined with metabolic therapy, immune support, and other evidence-based integrative interventions, it may meaningfully improve outcomes and quality of life.

At Holistic Healing LLC, we encourage anyone interested in high-dose melatonin for cancer support to work with a knowledgeable integrative healthcare provider who can guide dosing, monitor for any interactions with conventional treatments, and integrate melatonin appropriately into a comprehensive care plan.

Disclaimer

This blog post is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified and licensed healthcare professional before starting high-dose melatonin or any new supplement, especially during cancer treatment.